Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

ation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., USA, and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of and the potential market for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of the company's 8-K filed Oct. 21, 2008.

References

(1) Coakley E, et al. Second International Workshop Targeting HIV Entry. Oct. 20-21, 2006; Boston, MA, USA; No. 8.

(2) Dunkle LM, Greaves WL, et al. Long-Term Safety of Vicriviroc. 4
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... LITTLE FALLS, N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at The New York Palace Hotel in New ... December 2, 2014 at 2:00 PM ET. In addition, Mr. ... will be available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... Inc. (Nasdaq: OMCL ) a leading provider of ... present at the UBS 21st Annual Global Healthcare Services Conference ... Omnicell Speakers: Rob Seim, vice president & CFO ... Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: Grand ...
... 2011 Carrot Medical, a leading designer of integrated ... During the year, Carrot Medical achieved significant growth in ... private financing. Carrot Medical, recognized as a ... Technology solution that integrates medical images and other visual ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011 2
(Date:11/21/2014)... Porcelain veneer dentist, Dr. ... in preparation for the coming holiday season. Veneers, ultra-thin ... look completely natural, and can be used to permanently ... valued for their ability to strengthen teeth. Veneers are ... on one or several teeth to rejuvenate appearance. Check ...
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Seeking to make ... U.S. Food and Drug Administration on Thursday approved a ... Hydrocodone -- best known by the brand name ... been tied to a surge in dangerous addictions across ... approved Hysingla ER (hydrocodone bitartrate) is an extended-release tablet ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Certain genes might prevent regular ... a fifth of people with type 2 diabetes, a ... pondered by doctors working with diabetic patients, one expert ... the impression that exercise helps decrease insulin resistance in ... director of the Center for Weight Management at North ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Richard ... Solutions , will present advanced benefits administration strategies ... Annual Houston HR Leadership Summit. This Game Changer ... Resources industry to present cutting-edge solutions and best ... will explain how real-time data exchange between health ...
(Date:11/21/2014)... WOBURN, Mass. (PRWEB) November 21, 2014 ... two free workshops titled “Massachusetts Insurance Funding for Autism ... disorder (ASD) navigate their way through the insurance coverage ... covered under Massachusetts law and the most effective ways ... on Thursday, Dec. 4 from 6-8:00 p.m. at 331 ...
Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2
... Associates will host a community health fair in the Shoh-Sohail ... will include free health screenings for the local community, will ... VHA Building on the Mandalay Canal, 220 Las Colinas Blvd, ... will be hosted in an effort to inform, educate and ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... (NYSE: ABT ), Eli Lilly & Co. (NYSE: ... ), Novartis AG (NYSE: NVS ) and GlaxoSmithKline ...
... Feb. 18 SpectraScience, Inc. (OTC Bulletin Board: ... it will place its LUMA(R) Cervical Imaging System ... located in Edina, Minnesota.Dr. James B. Presthus, co-founder ... of the LUMA System represents our continued dedication ...
... affairs departments in deploying comprehensive investigator-initiated research grant management program ... ... 18, 2009 -- Clinipace, a growing clinical research solutions company, ... firms to deploy its TEMPO™ for Grant Management ...
... is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay News) ... human fetal stem cell therapy has been reported in Moscow, ... to the growths. , The tumors appeared along ... after he began receiving the neural fetal stem cell treatment ...
... Feb. 18 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of ... for the quarter ended December 31, 2008.In the fourth quarter ... compared to net revenue of $288.0 million in the fourth ...
Cached Medicine News:Health News:Las Colinas FREE Community Health Fair Benefiting the Shoh-Sohail Family of Irving 2Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 3Health News:Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 3Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 4Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 5Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 6Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 7Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 8Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 9Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 10Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 11Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 12Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 13Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 14Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 15Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 16Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 17Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 18
BD Beaver Phaco slit blade, 3.2 mm, angled 45, bevel up. matte finish offers a precise incision which minimizes leakage during phaco procedures. Precise incision minimizes leakage during phaco proced...
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... testing of large oculomotor imbalances ... all standard trial frames. Offer ... thin optical quality acrylic and ... a display box. Available as ...
... only powered 6-inch dermatome on the market. ... adult hands or a small child's face ... to run more efficiently, thus the motor ... temperature is much cooler. The Electro-Dermatome is ...
Medicine Products: